Drug
Sulfatinib
Sulfatinib is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
not_yet_recruiting125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_1
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT05590572
completedphase_1
Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT02133157
completedphase_1
A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
NCT02320409
completedphase_1
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NCT02267967
Clinical Trials (4)
Showing 4 of 4 trials
NCT05590572Phase 1
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT02133157Phase 1
Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT02320409Phase 1
A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
NCT02267967Phase 1
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4